Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
Search or
𝛼
SK
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 3.2/5
Celltrion Inc (068270 KS)
Watchlist
Contact IR
610
Analysis
Health Care
•
South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
01 Aug 2016 07:19
Alpha Generation & Share Buybacks in Korea
Korean companies are showing increasing willingness to buyback shares. Korea Stock Exchange announced that from beginning of this year to as of 27...
Douglas Kim
Follow
618 Views
Share
bearish
•
Celltrion Inc
•
27 Jul 2016 20:55
Another Payer Speaks Cautiously
Leading U.S. pharmacy benefits manager Express Scripts (ESRX US) held a conference call today to discuss its Q2: 2016 results. The company is the...
Kemp Dolliver, CFA
243 Views
Share
bullish
•
Thematic (Sector/Industry)
•
06 Jul 2016 16:13
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
Sanghyun Park
Follow
3.5k Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Jul 2016 01:24
What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....
If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the...
Douglas Kim
Follow
383 Views
Share
bearish
•
Celltrion Inc
•
11 Jun 2016 19:20
Study Highlights Hurdles to U.S. Uptake of Inflectra
A new study (abstract attached) presented at the European Union League Against Rheumatism (EULAR) Conference highlights one of the main hurdles to...
Kemp Dolliver, CFA
229 Views
Share
First
Previous
116
117
118
119
120
121
122
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.58.0
x